COSM

Record Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segments Total liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in convertible note and credit facility balances Stockholders' equity increased by $1.4M, or 7.6%, with the liabilities-to-assets ratio improving by 370 basis points Adjusted EBITDA near breakeven as increased revenue was offset by strategic investments to support global growth Record momentum continues into Q2 2026 with U.S. expansion actively underway CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Income Statement Cosmos Health delivered the highest Q1 revenue in Company history with continued progress toward adjusted profitability, reflecting broad-based commercial strength - over 75 new pharmacies added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories. Revenue was $17.93 million, an increase of 30.7% from $13.71 million in Q1 2025, reflecting strong sales momentum across all core divisions. Gross profit was $1.38 million in Q1 2026, compared to $2.05 million in Q1 2025, reflecting a revenue mix shift toward wholesale distribution activity at CosmoFarm, compounded by the aforementioned sales discount adjustment. Total operating expenses increased to $3.57 million in Q1 2026, compared to $2.88 million in Q1 2025, reflecting strategic investments in personnel, infrastructure, technology, and AI-driven efficiencies to support global growth initiatives. Net income (loss) was ($2.81 million) in Q1 2026, compared to ($0.82 million) in Q1 2025. The increase is driven principally by $1.15 million of non-cash, non-operational items: Adjusted EBITDA was ($229,596) in Q1 2026, near breakeven, as increased revenue was offset by higher expenses reflecting the Company's ongoing investments in global growth initiatives. Adjusted Net Income (Loss) was ($996,502), driven by $766,906 in interest expense incurred in support of the Company's growth investments. Balance Sheet Cosmos Health continued to improve its balance sheet in Q1 2026, with a...

By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT The latest earnings release from Cosmos Health Inc (NASDAQ: COSM) marks a clear inflection point in the company’s trajectory, with the financial results reinforcing a narrative of accelerating growth, improving operating efficiency, and expanding strategic optionality. The company delivered its strongest annual performance to date, with revenue reaching a record $65.3 million, representing 20% year-over-year growth—an outcome driven by strength across all core operating segments, including contract manufacturing, pharmaceutical distribution, and proprietary nutraceutical brands. What stands out most in this report is not simply the top-line growth, but the sharp improvement in profitability metrics. Gross profit surged 83% to $7.9 million, significantly outpacing revenue growth and driving a meaningful expansion in gross margin to 12.1%. This margin expansion reflects a favorable shift in product mix toward higher-value offerings, particularly within the company’s contract manufacturing division and branded product portfolio. It also signals that Cosmos is beginning to benefit from operating leverage as scale increases—an important milestone for a company that has historically operated at thinner margins. Further reinforcing this operational progress is the substantial improvement in earnings efficiency. Adjusted loss per share narrowed by approximately 82% year-over-year, indicating that while the company is not yet profitable on a GAAP basis, it is moving decisively in that direction. This trend, combined with an improvement in adjusted EBITDA, suggests that the underlying business is becoming structurally more efficient. Equally important is the dramatic strengthening of the balance sheet. Cash increased nearly tenfold to roughly $3.5 million, providing the company with significantly greater financial flexibility. This liquidity improvement is further amplified by the establishment of a $300 million financing facility, which positions Cosmos to pursue growth initiatives, including expansion of its manufacturing footprint, continued product development, and the buildout of a digital asset treasury strategy. While unconventional, this capital strategy underscores management’s willingness to explore non-traditional avenues to enhance shareholder value and fund expansion. From an operationa...

Scaled contract manufacturing division, securing long-term agreements for over 12 million units Expanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase orders for over 300,000 units across new markets Advanced R&D pipeline, securing patented anticancer drugs, multiple AI-driven patent filings, and CCX0722 weight management product entering final development Secured $300 million financing facility to launch digital asset treasury strategy CEO Greg Siokas increased ownership by over 3.3 million shares, reinforcing deep insider conviction Strong momentum continues into 2026 with record growth across all core segments and continued U.S. expansion underway CHICAGO, IL / ACCESS Newswire / April 15, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the full year ended December 31, 2025, delivering the strongest annual revenue performance in the Company's history. Full Year 2025 Financial Highlights Performance was marked by all-time high revenue, significant gross profit expansion, and margin improvement, driven by strong performance across core business segments, including scaling the contract manufacturing division at Cana Laboratories, increased volumes in the CosmoFarm wholesale distribution business supported by an expanded pharmacy network, solid sales growth through Decahedron in the United Kingdom, and the global expansion of proprietary brands, including Sky Premium Life and C-Scrub. Income Statement Revenue increased by 20% to $65.27 million in FY 2025, compared to $54.43 million in FY 2024, representing the highest annual revenue in Company history and reflecting strong performance across all core divisions. Gross profit increased by 83% to $7.90 million, compared to $4.31 million in FY 2024, driven by improved product mix, increased contribution from higher-margin divisions, and operational efficiencies. Gross margin expanded to 12.10%, compared to 7.92% in FY 2024, representing a 418-basis point improvement. Total operating expenses increased to $24.60 million, compared to $19.86 million in FY 2024, reflecting strategic investments in talent and new hires, including managerial, sales, and scientific personnel, corporate growth initiatives supporting global expansion, as well as extensive...

CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that C-Scrub Wash 4%, manufactured by its wholly owned subsidiary Cana Laboratories S.A., has successfully completed testing under EN 12791:2016+A1:2017, the European standard for surgical hand disinfection. The independent study, conducted by Quality Assurance & Control Systems Ltd. (QACS), a Greece-based testing and certification laboratory specializing in microbiological and disinfectant efficacy studies, confirmed that C-Scrub Wash 4% demonstrated effective antimicrobial activity for surgical hand disinfection in accordance with EN 12791 requirements. The product is formulated with 4% Chlorhexidine Digluconate and is designed for use in healthcare and clinical environments requiring high standards of hygiene and infection prevention. EN 12791 is a widely recognized European benchmark for surgical hand antisepsis products and supports entry into hospital, surgical, and professional healthcare channels. The Company believes that successful completion of this study strengthens the clinical positioning of C-Scrub Wash 4% and opens additional commercial opportunities across international healthcare markets. This milestone comes as C-Scrub continues gaining traction across several key markets, including the United Kingdom, where Cosmos Health has recently announced expanding commercial availability and growing market presence. The Company believes the EN 12791 study completion further supports its strategy to expand the C-Scrub portfolio across both retail and institutional healthcare channels. The Company believes that this achievement further strengthens Cosmos Health's infection control portfolio, enhances the commercial positioning of the C-Scrub brand, and supports continued international growth. Greg Siokas, CEO of Cosmos Health, stated: "The successful completion of the EN 12791 study for C-Scrub Wash 4% represents an important milestone for Cosmos Health. As demand for infection control solutions continues to grow across key markets, this achievement enhances the clinical credibility of our C-Scrub portfolio and supports expansion into hospital, surgical, and institutional healthcare markets globally. By achieving technical parity with established industry benc...

Continues to deliver record revenue and improving operating metrics Significant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75% NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibility Evaluating potential monetization of non-core assets to support more efficient capital allocation accelerate strategic investments address the current valuation disconnect, including options such as share repurchases Recent geopolitical turmoil has had a negligible impact on the Company’s operations, with record-breaking growth continuing at a strong pace To issue guidance update following the release of fourth quarter and full-year 2025 results Analyst coverage initiated by Zacks Small-Cap Research with a valuation of $4.50 per share CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided a corporate update and announced that it intends to issue updated operational, strategic, and financial guidance following the release of its fourth quarter and full-year 2025 financial results. Record Operating Momentum Cosmos Health continues to deliver record revenue and gross profit while improving operating metrics, reflecting disciplined execution across all core divisions. Management believes the Company is progressing toward sustained profitability as revenue continues to grow, scale efficiencies crystallize, and margins improve. The war in the Middle East and recent geopolitical turmoil have had a negligible impact on the Company’s operations. The Company expects record-breaking growth to continue at a strong pace as it advances toward sustained profitability. Strong Growth Amid Significant U.S. Expansion & Partnerships with Leading Retailers Recent milestones include the continued global expansion of the Company’s proprietary brands. Sky Premium Life is growing across Europe...

CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Income Statement Cosmos Health delivered solid results in Q1 2025, highlighted by a significant increase in gross profit and positive performance on both an Adjusted EBITDA and Adjusted Net Income basis, reflecting a meaningful turnaround in bottom-line performance. Revenue for Q1 2025 was $13.71 million, a decrease of 5.98% from $14.58 million in Q1 2024, primarily reflecting the Company’s strategic shift toward higher-margin focus areas and a disciplined reduction of promotional-dependent activities. Gross profit increased by 53.70% to $2.05 million, up from $1.33 million in the prior-year period, driven by an improved product mix and operational leverage. Segment contributions were as follows: Wholesale logistics distribution: $1.18 million Owned nutraceuticals/pharmaceuticals and manufacturing: $0.87 million Gross margin expanded by 581 basis points to 14.95%, compared to 9.14% in Q1 2024, reflecting a greater focus on higher-margin segments, including contract manufacturing and proprietary brands, as well as operational synergies realized at Cana Laboratories. Total operating expenses declined by 9.05% to $2.88 million, compared to $3.17 million in Q1 2024, reflecting: 17.34% reduction in salaries and wages, driven by efficiency initiatives 83.78% decline in sales and marketing expenses, due to a strategic reduction in promotional spend 14.46% decrease in general and administrative expenses, adjusted for non-cash items Net loss narrowed by 56.17% to $0.82 million, down from $1.87 million in the prior-year period. The loss was primarily attributable to costs related to the Company’s Nasdaq U.S. listing. Return to Profitability On an adjusted basis, Cosmos Health delivered profitable results in both EBITDA and Net Income, driven by improved gross profitability and disciplined cost management. Adjusted EBITDA increased by 157.8% to $0.37 million, compared to a loss of $0.64 million in Q1 2024. A...

CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gains recognized in the prior year. Revenue increased by 2.0% to $54.43 million in FY 2024, from $53.38 million in the prior year, driven primarily by sustained organic growth and continued contributions from prior acquisitions. Gross margin was 7.92%, compared to 8.15% in FY 2023, reflecting a greater mix of revenue from the lower-margin logistics distribution segment. Total operating expenses declined by 24.16% to $19.86 million, compared to $26.18 million in FY 2023. This includes: 40.26% reduction in general and administrative expenses. 71% decrease in sales and marketing expenses, following a strategic reduction in promotional spend. Total other income, net, was a loss of $0.64 million in FY 2024, compared to income of $3.29 million in FY 2023. The year-over-year decline was primarily due to the absence of non-cash gains recognized in the prior year, including: $1.91 million gain on debt extinguishment. $1.44 million bargain purchase gain related to the acquisition of Cana Laboratories. Adjusted EBITDA was negative $3.73 million, compared to positive $0.06 million in FY 2023, while Adjusted net loss widened to $4.74 million from $0.81 million. Balance Sheet: The liabilities-to-assets ratio remains a modest 55% as of year-end 2024, reflecting a balanced capital structure and continued financial discipline. Total assets decreased by 17.72% to $54.31 million as of December 31, 2024, from $66.01 million at the end of 2023, while the Company continued to maintain a well-diversified asset base, supported by the following key components: Tangible asset base, with property and equipment, net, totaling $9.69 million, largely reflecting the Company’s wholly owned real estate assets, in...